Page 13 - குழு க்கு மருத்துவ ப்ராடக்ட்ஸ் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article Share this article INDIANAPOLIS, March 5, 2021 /PRNewswire/ Eli Lilly and Company (NYSE: LLY) announced today that the European Medicines Agency s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive scientific opinion for bamlanivimab alone and bamlanivimab administered together with etesevimab. The opinion advises bamlanivimab alone and bamlanivimab administered together with etesevimab can be used for the treatment of confirmed COVID-19 in patients aged 12 years and older that do not require supplemental oxygen for COVID-19 and who are at high risk of progressing to severe COVID-19. The CHMP scientific opinion under Article 5.3 of regulation 726/2004 provides a harmonized, EU-level opinion on the efficacy, quality, and safety of the antibodies. The opinion can now be considered by the EU member states when making decisions on the use of the therapies at a national level before a formal marketing authorization is issued.

United statesCzech republicDavida ricksMolly mccullyKevin hernPrnewswire eli lillyDani barnhizerJunshi biosciencesEli lillyVaccine research centerClinical worsening after bamlanivimab administrationInstitute of microbiologyNational institute of allergyChinese academy of scienceMelinda gates foundationCommittee for medicinal products